Skip to content
Poster

Metabolic effects of survodutide in DIO mice at thermoneutrality

Background & aim:

Survodutide is a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), currently in clinical development for obesity and related metabolic disorders. By concurrently enhancing GCGR and GLP1R signaling, survodutide offers a synergistic approach to improving metabolic function. The present study aimed to evaluate the effects of survodutide on metabolic markers and energy expenditure (EE) in diet-induced obese (DIO) mice.

Subjects
MouseDIO mouseBody compositionBody weightBlood biochemistryObesityEnergy expenditure monitoringGLP-1 receptorGlucagon receptorHistopathology scoreLiver morphometryReal-time food intake/activity analysisSurvodutide

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top